Navigation Links
PRC Government Grants High-Tech Status to AOBO Subsidiaries
Date:1/13/2009

NEW YORK, Jan. 13 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOBO" or "the Company"), a leading marketer, distributor and manufacturer of pharmaceutical and healthcare products in China, today announced that the PRC government, led by the Ministry of Science and Technology of China, the Ministry of Finance and the State Administration of Taxation, jointly granted three of the company's subsidiaries, Heilongjiang Songhuajiang Pharmaceutical Co., Ltd. ("HSPL"), Changchun Xin'an Pharmaceutical Co., Ltd. ("CCXA"), and Three Happiness Bioengineering Co., Ltd. ("Three Happiness") high-tech enterprise status. Prior to today's announcement, AOBO's other two subsidiaries: Guangxi BOKE Pharmaceutical Co., Ltd. ("BOKE") and Guangxi Lingfeng Pharmaceutical Co., Ltd. ("GLP") were already approved for the designation from the local provincial government, and the Company anticipates finalizing the certification from the central government in the near future. With today's announcement, five of AOBO's subsidiaries, throughout different provinces, have received recognition to benefit from a 15 percent tax rate through 2011, at the subsidiary level. Additionally, according to the China Banking Regulatory Commission Guiding Opinions Number 94, companies with high-tech status are eligible for benefits in addition to the 15 percent tax rate, potentially including preferential treatment in obtaining other support from the government such as obtaining financial support from the PRC's special Technological Development Fund, and to receive competitive commercial bank loans and subsidized interest.

Mr. Tony Liu, Chairman and CEO of AOBO, stated, "Receipt of high-tech enterprise status further demonstrates the fundamental strength of our business particularly related to our proprietary products and innovation at the subsidiary level. By having this recognition from the government, we are laying the groundwork for our future growth with eligibility for government funding and grant incentives. We are truly proud that AOBO achieved this esteemed status, especially given that very few companies have successfully achieved this status."

High-tech status is awarded by the PRC to recognize companies that consistently invest in new product development, and have substantial revenues generated by their own proprietary patented or innovative products. In this way, the Chinese government encourages domestic and foreign investment in advanced technologies, and has created a series of preferential tax policies to stimulate and promote the production of high-tech products, the provision of high-tech related services and technology transfers into and within China. The Ministry of Science and Technology of China, the Ministry of Finance and the State Administration of Taxation jointly promulgated the Measures For the Recognition and Administration of New and High-Tech Enterprises, which clearly specifies the requirements for the recognition and administration of new and high-tech enterprises.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended September 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Maureen Mo Zilly Joins the Varian Medical Systems Government Affairs Team as Director, Federal Affairs
2. Atlantica Bioenergy Task Force hosts industry and government leaders
3. SenesTech, Inc. Commences Product Registration Process With Australian Government
4. San Diego universities, government and industry rally around local Clean-Tech cluster
5. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
6. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
7. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
8. Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers
9. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
10. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
11. BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):